Dana C. Matthews, MD, is director of clinical hematology at Seattle Childrens Hospital and head of the Pediatric Hemophilia Program; she is associate professor at the University of Washington School of Medicine. Her research interests include risk-based optimization of the treatment of pediatric thrombosis, clinical outcomes in patients with hemophilia, and novel treatments for immune thrombocytopenic purpura (ITP).
Current and pending research includes involvement in an international project to characterize immune responses to factor VIII that result in inhibiting antibodies, a multicenter pediatric trial of a thrombopomimetic agent in ITP, and pilot pediatric studies of a novel oral anticoagulant. She is interested in improving the outcome for pediatric patients with thrombosis by developing a pediatric thrombosis registry and developing clinical trials for subgroups of patients with thrombosis. She is medical director of the Anticoagulation Service for Seattle Childrens Hospital, and chair of the Blood Usage Committee. National responsibilities include membership on the Certification and Continuing Education Committee and the Nominating Committee of the American Society of Pediatric Hematology/Oncology. She is a member of the Board of Directors of the American Board of Pediatrics, and is completing a term on the hematology-oncology subboard. She will be Medical Editor for that subboard beginning in 2011.